The impact of levodopa on post-stroke depression: the ESTREL-depression-study.
Sauter MI., Kaufmann JE., Boos L., Zietz A., Trüssel S., Luft AR., Polymeris A., Altersberger VL., Wiesner K., Wiegert M., Held JPO., Rottenberger Y., Schwarz A., Medlin F., Accolla EA., Foucras S., Kägi G., De Marchis GM., Politz S., Greulich M., Tarnutzer AA., Sturzenegger R., Katan M., Arnold M., Nedeltchev K., Schär J., Deglon KVDK., Rapin P-A., Salerno A., Seiffge DJ., Auer E., Lippert J., Bonati LH., Schuster-Amft C., Gäumann S., Chabwine JN., Humm A., Möller JC., Schweinfurther R., Bujan B., Jedrysiak P., Sandor PS., Gonzenbach R., Mylius V., Lutz D., Lienert C., Peters N., Michel P., Müri RM., Schädelin S., Hemkens LG., Ford GA., Lyrer PA., Gensicke H., Traenka C., Engelter ST.
INTRODUCTION: Post-stroke depression (PSD) frequently occurs after acute stroke and negatively affects rehabilitation. Dopamine has beneficial effects on motivation and emotional stability. In stroke patients, low dopamine levels are linked to PSD. This study investigated whether levodopa treatment during in-hospital rehabilitation impacts PSD compared to placebo. PATIENTS AND METHODS: ESTREL-Depression was a pre-planned analysis of the multicenter, randomized, double-blind, placebo-controlled ESTREL trial. Participants with an acute ischemic or hemorrhagic stroke were randomly assigned to receive either levodopa/carbidopa (100/25 mg) or placebo three times daily for 39 days. All ESTREL participants with (1) information about the presence or absence of depression at three months and (2) who took at least 80% of the study medication were eligible for the study. Participants with a history of depression were excluded. For the primary outcome, the presence of PSD was defined as having a T-score of ≥55 in the Patient-Reported Outcomes Measurement Information System short-form depression-4a 3 months after randomization. Binary logistic regression was performed to assess the effect of levodopa on PSD. RESULTS: The study included 407 ESTREL participants (median age 72, 60% male), 209 receiving levodopa, and 198 receiving placebo. At 3 months, the frequency and odds of PSD did not differ between the levodopa group (26%) and the placebo group (28%) (OR = 0.93, 95% CI, 0.60-1.43). CONCLUSION: In the ESTREL-Depression study, treatment with levodopa had no impact on the occurrence of PSD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03735901 (https://clinicaltrials.gov/study/NCT03735901).